CORT
Another biotech headache
Corcept Therapeutics is back in the spotlight for the kind of reason management never puts on a slide deck. Hagens Berman says investors in CORT are staring down an April 21, 2026 lead-plaintiff deadline in a securities class action tied to the company’s FDA rejection of relacorilant and a separate federal court patent loss.
The allegation in plain English
The complaint claims Corcept talked up relacorilant’s future while allegedly sitting on repeated FDA warnings that the data weren’t strong enough. In other words: the company was playing upbeat trailer music while regulators were apparently watching the blooper reel.
The key beats here are:
- The class period runs from October 31, 2024 to December 30, 2025
- The FDA issued a Complete Response Letter on December 31, 2025
- The lawsuit says investors were kept in the dark about how shaky the evidence really was
Why investors should care
This isn’t just legal paperwork for the fine-print crowd. Securities suits can mean distraction, legal costs, and a fresh reason for the market to keep a skeptical eye on the pipeline. For a biotech, confidence is half the stock chart.
Big picture
The CRL was already a punch to the gut; the class action turns it into a longer-running headache. Even if the science story eventually improves, the market now has another question mark to price in.